Category: Prostate Cancer

ZCL278 is a Selective Cdc42 Inhibitor, with Antiviral Activity

Cdc42 is a member of the Rho GTPase family of low molecular weight G proteins. It is an important regulator of many biological processes. Besides, Cdc42 plays key roles in cytoskeletal organization, vesicular trafficking, cell cycle control, and transcription. As with most GTPases, transduction of signals occurs through the...

FPA-124 is a Selective Akt Inhibitor and Induces Apoptosis

Copper complexes play an important role in the active sites of a large number of metalloproteins in biological systems. Copper complexes also have a potential application for numerous catalytic processes in living organisms. In addition, copper complexes involve electron transfer reactions or activation of some antitumor substances. In this...

Niraparib is an Orally Active PARP Inhibitor

Poly (ADP-ribose) polymerases (PARPs) are a family of related enzymes. PARP shares the ability to catalyze the transfer of ADP-ribose to target proteins. PARP plays an important role in various cellular processes, including modulation of chromatin structure, transcription, replication, recombination, and DNA repair. Niraparib (MK-4827) is a potent PARP...

AG-825, a selective ErbB2 inhibitor with anti-cancer effect

The ErbB tyrosine kinase receptor (RTK) family has 4 members: ErbB1 (EGFR/HER1), ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4). These receptors are cell surface receptors and play important roles in cell proliferation, survival, and growth signaling. ErbB2 is an orphan receptor; it can associate with other ErbBs to enhances...

CG-200745, a HDAC Inhibitor, Induces the Accumulation of p53

Histone deacetylase (HDAC) inhibits are considered to be promising agents that can be used as treatments for cancer. CG-200745 is a novel and potent hydroxamate-based pan-HDAC inhibitor. CG-200745 has the hydroxamic acid moiety to bind zinc at the bottom of the catalytic pocket. We will introduce its anti-tumorigenic property...

CSRM617 is a Transcription Factor ONECUT2 Inhibitor for Prostate Cancer

The transcription factor ONECUT2 (OC2) is a master regulator of androgen receptor networks in mCRPC (metastatic castration-resistant prostate cancer ). OC2 acts as a survival factor in mCRPC models. OC2 is a potential drug target in the metastatic phase of aggressive PC. CSRM617,  a well-tolerated novel small-molecule inhibitor of...

VERU-111 is an Orally Active Tubulin Inhibitor

Microtubules play a critical role in the proliferation of cancer cells. Meanwhile, microtubule dynamics is therefore one of the most productive therapeutic targets for cancer treatment. Microtubule-targeting agents can interfere with functions of microtubules, thereby disrupting the formation of the mitotic spindle, eventually leading to mitotic arrest at the...